Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Immunologic targets in psoriasis.

× No keyword cloud information.

14 in total

1. Etanercept monotherapy in psoriasis.

Authors: Christopher T Ritchlin
Journal: Curr Rheumatol Rep Date: 2004-08 Impact factor: 4.592

2. Pattern VEP alterations in psoriatic patients may indicate a sub clinic optic neuritis.

Authors: M Perossini; E Turio; T Perossini; M Romagnoli; S Benedetti; G Cei; P Barachini; M Nardi
Journal: Doc Ophthalmol Date: 2005 Mar-May Impact factor: 2.379

3. Hapten application to the skin induces an inflammatory program directing hapten-primed effector CD8 T cell interaction with hapten-presenting endothelial cells.

Authors: Danielle D Kish; Nina Volokh; William M Baldwin; Robert L Fairchild
Journal: J Immunol Date: 2011-01-14 Impact factor: 5.422

4. CD43 is a ligand for E-selectin on CLA+ human T cells.

Authors: Robert C Fuhlbrigge; Sandra L King; Robert Sackstein; Thomas S Kupper
Journal: Blood Date: 2005-11-03 Impact factor: 22.113

Review 5. [Psoriasis SCID-mouse model].

Authors: J Pfeffer; R Kaufmann; W-H Boehncke
Journal: Hautarzt Date: 2006-07 Impact factor: 0.751

Review 6. Immunopathology of psoriasis and psoriatic arthritis.

Authors: D J Veale; C Ritchlin; O FitzGerald
Journal: Ann Rheum Dis Date: 2005-03 Impact factor: 19.103

Review 7. New insights into atopic dermatitis.

Authors: Donald Y M Leung; Mark Boguniewicz; Michael D Howell; Ichiro Nomura; Qutayba A Hamid
Journal: J Clin Invest Date: 2004-03 Impact factor: 14.808

8. Weight-Based Adaptation of TNF-Antagonist Induction versus Maintenance Dose.

Authors: Alexander A Navarini; Marco A Muster; Antonios G A Kolios; Philipp Fritsche; Martin Glatz; Lars E French; Ralph M Trüeb
Journal: Case Rep Dermatol Date: 2011-06-18

Review 9. Off-label biologic regimens in psoriasis: a systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapy.

Authors: Elizabeth A Brezinski; April W Armstrong
Journal: PLoS One Date: 2012-04-11 Impact factor: 3.240

10. Progesterone for the prevention of preterm birth: indications, when to initiate, efficacy and safety.

Authors: Helen Y How; Baha M Sibai
Journal: Ther Clin Risk Manag Date: 2009-03-26 Impact factor: 2.423